Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatment
NEW ORLEANS, May 10, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that its scientific team will be leading a virtual panel discussion on the future of autoimmune disease treatment on May 11, 2022.
The panel will address next generation drugs in development, including Revolo’s immune resetting drugs ‘1805 and ‘1104.
About Revolo Biotherapeutics
For further information, please visit www.revolobio.com.